709 related articles for article (PubMed ID: 25878112)
1. Novel CD4-Based Bispecific Chimeric Antigen Receptor Designed for Enhanced Anti-HIV Potency and Absence of HIV Entry Receptor Activity.
Liu L; Patel B; Ghanem MH; Bundoc V; Zheng Z; Morgan RA; Rosenberg SA; Dey B; Berger EA
J Virol; 2015 Jul; 89(13):6685-94. PubMed ID: 25878112
[TBL] [Abstract][Full Text] [Related]
2. Bispecific chimeric antigen receptors targeting the CD4 binding site and high-mannose Glycans of gp120 optimized for anti-human immunodeficiency virus potency and breadth with minimal immunogenicity.
Ghanem MH; Bolivar-Wagers S; Dey B; Hajduczki A; Vargas-Inchaustegui DA; Danielson DT; Bundoc V; Liu L; Berger EA
Cytotherapy; 2018 Mar; 20(3):407-419. PubMed ID: 29306566
[TBL] [Abstract][Full Text] [Related]
3. Neutralization of human immunodeficiency virus type 1 by sCD4-17b, a single-chain chimeric protein, based on sequential interaction of gp120 with CD4 and coreceptor.
Dey B; Del Castillo CS; Berger EA
J Virol; 2003 Mar; 77(5):2859-65. PubMed ID: 12584309
[TBL] [Abstract][Full Text] [Related]
4. sCD4-17b bifunctional protein: extremely broad and potent neutralization of HIV-1 Env pseudotyped viruses from genetically diverse primary isolates.
Lagenaur LA; Villarroel VA; Bundoc V; Dey B; Berger EA
Retrovirology; 2010 Feb; 7():11. PubMed ID: 20158904
[TBL] [Abstract][Full Text] [Related]
5. HIV-1-Specific Chimeric Antigen Receptor T Cells Fail To Recognize and Eliminate the Follicular Dendritic Cell HIV Reservoir
Ollerton MT; Berger EA; Connick E; Burton GF
J Virol; 2020 May; 94(10):. PubMed ID: 32161179
[TBL] [Abstract][Full Text] [Related]
6. Antiviral Activity of HIV gp120-Targeting Bispecific T Cell Engager Antibody Constructs.
Brozy J; Schlaepfer E; Mueller CKS; Rochat MA; Rampini SK; Myburgh R; Raum T; Kufer P; Baeuerle PA; Muenz M; Speck RF
J Virol; 2018 Jul; 92(14):. PubMed ID: 29720517
[TBL] [Abstract][Full Text] [Related]
7. Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4+ T Lymphocytes Isolated from HIV-1-Infected Individuals Receiving Suppressive Combined Antiretroviral Therapy.
Liu B; Zou F; Lu L; Chen C; He D; Zhang X; Tang X; Liu C; Li L; Zhang H
J Virol; 2016 Nov; 90(21):9712-9724. PubMed ID: 27535056
[TBL] [Abstract][Full Text] [Related]
8. A Trispecific Anti-HIV Chimeric Antigen Receptor Containing the CCR5 N-Terminal Region.
Hajduczki A; Danielson DT; Elias DS; Bundoc V; Scanlan AW; Berger EA
Front Cell Infect Microbiol; 2020; 10():242. PubMed ID: 32523897
[TBL] [Abstract][Full Text] [Related]
9. Antibody 17b binding at the coreceptor site weakens the kinetics of the interaction of envelope glycoprotein gp120 with CD4.
Zhang W; Godillot AP; Wyatt R; Sodroski J; Chaiken I
Biochemistry; 2001 Feb; 40(6):1662-70. PubMed ID: 11327825
[TBL] [Abstract][Full Text] [Related]
10. Engineering HIV-Resistant, Anti-HIV Chimeric Antigen Receptor T Cells.
Hale M; Mesojednik T; Romano Ibarra GS; Sahni J; Bernard A; Sommer K; Scharenberg AM; Rawlings DJ; Wagner TA
Mol Ther; 2017 Mar; 25(3):570-579. PubMed ID: 28143740
[TBL] [Abstract][Full Text] [Related]
11. HIV-1-Specific Chimeric Antigen Receptors Based on Broadly Neutralizing Antibodies.
Ali A; Kitchen SG; Chen ISY; Ng HL; Zack JA; Yang OO
J Virol; 2016 Aug; 90(15):6999-7006. PubMed ID: 27226366
[TBL] [Abstract][Full Text] [Related]
12. Differential CD4/CCR5 utilization, gp120 conformation, and neutralization sensitivity between envelopes from a microglia-adapted human immunodeficiency virus type 1 and its parental isolate.
Martín J; LaBranche CC; González-Scarano F
J Virol; 2001 Apr; 75(8):3568-80. PubMed ID: 11264346
[TBL] [Abstract][Full Text] [Related]
13. Sequential CD4-coreceptor interactions in human immunodeficiency virus type 1 Env function: soluble CD4 activates Env for coreceptor-dependent fusion and reveals blocking activities of antibodies against cryptic conserved epitopes on gp120.
Salzwedel K; Smith ED; Dey B; Berger EA
J Virol; 2000 Jan; 74(1):326-33. PubMed ID: 10590121
[TBL] [Abstract][Full Text] [Related]
14. Structural mechanism of trimeric HIV-1 envelope glycoprotein activation.
Tran EE; Borgnia MJ; Kuybeda O; Schauder DM; Bartesaghi A; Frank GA; Sapiro G; Milne JL; Subramaniam S
PLoS Pathog; 2012; 8(7):e1002797. PubMed ID: 22807678
[TBL] [Abstract][Full Text] [Related]
15. An immunoglobulin fusion protein based on the gp120-CD4 receptor complex potently inhibits human immunodeficiency virus type 1 in vitro.
Vu JR; Fouts T; Bobb K; Burns J; McDermott B; Israel DI; Godfrey K; DeVico A
AIDS Res Hum Retroviruses; 2006 Jun; 22(6):477-90. PubMed ID: 16796521
[TBL] [Abstract][Full Text] [Related]
16. Multiple determinants are involved in HIV coreceptor use as demonstrated by CCR4/CCL22 interaction in peripheral blood mononuclear cells (PBMCs).
Agrawal L; Vanhorn-Ali Z; Alkhatib G
J Leukoc Biol; 2002 Nov; 72(5):1063-74. PubMed ID: 12429730
[TBL] [Abstract][Full Text] [Related]
17. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C
Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249
[TBL] [Abstract][Full Text] [Related]
18. Antigenic properties of the human immunodeficiency virus envelope during cell-cell fusion.
Finnegan CM; Berg W; Lewis GK; DeVico AL
J Virol; 2001 Nov; 75(22):11096-105. PubMed ID: 11602749
[TBL] [Abstract][Full Text] [Related]
19. Unique binding modes for the broad neutralizing activity of single-chain variable fragments (scFv) targeting CD4-induced epitopes.
Tanaka K; Kuwata T; Alam M; Kaplan G; Takahama S; Valdez KPR; Roitburd-Berman A; Gershoni JM; Matsushita S
Retrovirology; 2017 Sep; 14(1):44. PubMed ID: 28938888
[TBL] [Abstract][Full Text] [Related]
20. Interaction with CD4 and antibodies to CD4-induced epitopes of the envelope gp120 from a microglial cell-adapted human immunodeficiency virus type 1 isolate.
Martín-García J; Cocklin S; Chaiken IM; González-Scarano F
J Virol; 2005 Jun; 79(11):6703-13. PubMed ID: 15890908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
